StockNews.com Begins Coverage on Syros Pharmaceuticals (NASDAQ:SYRS)

StockNews.com began coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a research note released on Friday morning. The brokerage issued a sell rating on the stock.

A number of other analysts have also weighed in on the company. HC Wainwright restated a “neutral” rating and set a $1.00 target price (down previously from $6.00) on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. TD Cowen restated a “hold” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. JMP Securities reiterated a “market perform” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. Finally, Brookline Capital Management reiterated a “hold” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and one has given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $3.33.

Syros Pharmaceuticals Price Performance

SYRS stock opened at $0.21 on Friday. Syros Pharmaceuticals has a 1-year low of $0.18 and a 1-year high of $7.96. The business has a 50-day moving average price of $0.23 and a 200 day moving average price of $1.95. The company has a market capitalization of $5.67 million, a P/E ratio of -0.07 and a beta of 1.31.

Syros Pharmaceuticals (NASDAQ:SYRS) last posted its quarterly earnings results on Thursday, October 31st. The company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($0.76) by $0.08. During the same quarter in the prior year, the business posted ($1.35) earnings per share. On average, analysts anticipate that Syros Pharmaceuticals will post -2.94 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Nancy A. Simonian sold 134,713 shares of the company’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $0.27, for a total transaction of $36,372.51. Following the transaction, the director now owns 41,070 shares in the company, valued at $11,088.90. This represents a 76.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 12.26% of the company’s stock.

Institutional Trading of Syros Pharmaceuticals

An institutional investor recently raised its position in Syros Pharmaceuticals stock. Exome Asset Management LLC grew its stake in Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) by 87.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 298,575 shares of the company’s stock after buying an additional 139,400 shares during the period. Exome Asset Management LLC owned 1.11% of Syros Pharmaceuticals worth $642,000 at the end of the most recent quarter. 91.47% of the stock is owned by institutional investors.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.